Edgewise Therapeutics, Inc. (EWTX) DCF Valuation

Edgewise Therapeutics, Inc. (EWTX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Edgewise Therapeutics, Inc. (EWTX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (EWTX) DCF Calculator empowers you to evaluate Edgewise Therapeutics, Inc. valuation using up-to-date financial data and offers complete flexibility to modify all key parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -9.8 -17.0 -42.9 -67.1 -112.8 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .1 .2 .3 .5 1.7 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -9.9 -17.2 -43.2 -67.6 -114.5 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 23.7 129.1 280.8 351.9 318.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .7 1.6 3.8 6.1 4.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.2 -.2 -.7 -5.5 -5.7 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -9.7 -17.1 -42.5 -53.6 -114.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -9.1 -16.2 -40.7 -56.4 -120.6 -4.0 .0 .0 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF -3.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -81
Equity Value 77
Diluted Shares Outstanding, MM 64
Equity Value Per Share 1.21

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real EWTX financials.
  • Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effects of your inputs on Edgewise Therapeutics’ valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Comprehensive EWTX Data: Pre-loaded with Edgewise Therapeutics' historical performance metrics and future growth estimates.
  • Tailorable Input Options: Modify parameters such as revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
  • Adaptive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined inputs.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
  • Intuitive Interface: Clean, organized design suitable for both industry experts and novices.

How It Works

  • Step 1: Download the prebuilt Excel template with Edgewise Therapeutics' (EWTX) data included.
  • Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Edgewise Therapeutics' intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose This Calculator for Edgewise Therapeutics, Inc. (EWTX)?

  • Accurate Data: Up-to-date Edgewise Therapeutics financials provide trustworthy valuation outcomes.
  • Customizable: Modify crucial parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you the effort of starting from scratch.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Edgewise Therapeutics stock (EWTX).
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Edgewise Therapeutics (EWTX).
  • Consultants: Deliver professional valuation insights on Edgewise Therapeutics (EWTX) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like Edgewise Therapeutics (EWTX) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Edgewise Therapeutics (EWTX).

What the Template Contains

  • Pre-Filled DCF Model: Edgewise Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Edgewise Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

Es wurden keine passenden Produkte gefunden.